Clinical And Cost- Effectiveness of Allium Sativum Oil (Garlic Oil ) Versus Mineral Trioxide Aggregate in Primary Molars Pulpotomy in Group of Egyptian Children : A Randomised Clinical Pilot Study.

Clinical And Cost- Effectiveness of Allium Sativum Oil Versus Mineral Trioxide Aggregate in Primary Molars Pulpotomy in Group of Egyptian Children : A Randomised Clinical Pilot Study.

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04903808

Enrollment

Registered

2021-05-27

Start date

2021-09-30

Completion date

2022-10-31

Last updated

2021-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carious Primary Molars

Keywords

Allium sativum oil, MTA, pulpotomy

Brief summary

Allium Sativum oil is advocated to prove the capability of new natural products in replacing higher cost pharmacological materials, while achieving the same successful clinical and radiographic long-term results.

Detailed description

One of the most challenging subjects in paediatric dentistry is choosing the ideal pulp medication material that has the required properties such as preserving the vitality of the remaining intact pulp and stimulating its repair. This material should prevent pathological root resorption.Clinical and cost effectiveness trials from different countries are useful to determine which medicament should be advocated in which economic setting . Alternative pulpotomy materials clinically effective as MTA but with lower cost should be studied .

Interventions

DRUGMineral Tri-Oxide Aggregate

ProRoot MTA, Dentsply

DRUGAllium Sativum Oil

Garlic oil Captain Company (CAP-PHARM)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Masking description

participants and outcome assessor will be blinded (double blind study )

Intervention model description

It is a double-blinded randomised clinical trial with equal randomisation parallel design with allocation ratio 1:1

Eligibility

Sex/Gender

ALL

Age

5 Years to 7 Years

Healthy volunteers

Yes

Inclusion criteria

* Apparently healthy children aged from 5- 7 years. * Children not having antibiotics in the past 14 days. * Cooperative children. * Children are having at least two carious asymptomatic second primary molars.

Exclusion criteria

* Uncooperative children. * Immunocompromised children. * Children with clinical or radiographic symptoms

Design outcomes

Primary

Measure	Time frame	Description
Clinical effectiveness	1 year follow up	clinical effectiveness will be measured by intraoral examination and radiographic assessment

Secondary

Measure	Time frame	Description
Cost-effectiveness	1 year follow up	cost-effectiveness will be measured with incremental cost-effectiveness ratio (ICER)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026